Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Assessment of Dose Proportionality of Three Dose Strengths (6 mg, 12 mg and 24 mg) over the Clinical Dose Range (6-48 mg) of the Newly Developed Once-Daily Extended Release Tablet Formulation of Deutetrabenazine

Tracking the immune response to SARS-CoV-2 mRNA booster vaccination in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS clinical trial)